Longevity Peptides Ranked: Evidence, Mechanisms, and Research Use Cases

Ranking longevity research compounds requires a framework for evaluation. The most widely used scientific framework is the hallmarks of aging (Lopez-Otin et al., *Cell*, 2013; updated 2023), which identifies the core biological processes driving aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

The best longevity research compounds address multiple hallmarks simultaneously or address a single hallmark with high mechanistic specificity. Evidence quality — the rigor of published research — is a separate dimension: preclinical animal data is informative, but human RCT data provides a qualitatively different level of evidence. The ranking below evaluates compounds on: (1) evidence quality tier, (2) number of aging hallmarks addressed, (3) mechanistic specificity, and (4) translational potential.

This comparison covers the five longevity compounds available for research through Blackwell BioLabs. Other longevity compounds with active research programs (rapamycin, senolytics, caloric restriction mimetics) are outside the scope of this comparison.

The following table ranks the five compounds across the key dimensions relevant to longevity research design.

Evidence Tier Key: ★★★★★ = Multiple human RCTs | ★★★★☆ = Phase 2 human trials or skin RCTs | ★★★☆☆ = Human cohort data or strong animal models

For researchers choosing compounds: NAD+ and SS-31 have the clearest human evidence trail. MOTS-c and Epithalon are mechanistically compelling but require human RCT confirmation. GHK-Cu bridges both tiers: strong human evidence in skin/wound contexts, extrapolated evidence for systemic aging.

NAD+ earns the top ranking on evidence quality alone. Multiple published randomized controlled trials in human subjects have demonstrated that NAD+ precursor supplementation (NMN and NR) produces measurable increases in tissue NAD+ levels and improvements in aging-related biomarkers including insulin sensitivity, muscle function, and inflammatory markers.

Key published human data: Mills et al. (2016, *Cell Metabolism*) — NMN supplementation in 10 middle-aged and older men over 10 weeks improved muscle insulin sensitivity and physical performance markers. Dollerup et al. (2018, *Cell Metabolism*) — NR supplementation increased NAD+ metabolome levels in healthy middle-aged and older adults. Multiple subsequent trials have confirmed that oral NAD+ precursors reliably increase blood and tissue NAD+ levels in humans at doses of 300-1000 mg/day.

The mechanistic rationale is among the most solid in longevity research: NAD+ declines with age in a pattern that is measurable, reproducible, and consistent across species. Restoring NAD+ levels activates the sirtuin deacylases (SIRT1-7) that regulate DNA repair, mitochondrial biogenesis, and inflammation — addressing multiple aging hallmarks through a well-characterized biochemical pathway. The PARP competition mechanism (PARP enzymes consume NAD+ during DNA repair; age-related DNA damage drives NAD+ depletion, which can be interrupted by NAD+ repletion) provides a clear mechanistic explanation for why NAD+ declines with age and how repletion could interrupt this cycle.

For researchers starting a longevity compound research protocol, NAD+ is the most evidence-supported choice as an anchor compound around which other mechanistically distinct agents can be added.

SS-31 (Elamipretide) ranks second on the strength of its clinical development history — it is the only peptide in this comparison with published Phase 2 clinical trial data from multiple indications. Stealth BioTherapeutics' clinical program in Barth syndrome (a genetic cardiolipin disorder), heart failure (PROGRESS-HF trial), and primary mitochondrial disease produced published Phase 2 data that constitutes human evidence at a different tier than observational cohort studies.

Published Phase 2 findings include: measurable improvements in exercise capacity (6-minute walk distance) in Barth syndrome patients, statistically significant reductions in left ventricular end systolic volume (LVESV) in heart failure subjects in PROGRESS-HF, and improvements in patient-reported functional outcomes in primary mitochondrial disease subjects. The cardiolipin biomarker data — showing that elamipretide treatment normalizes cardiolipin composition in treated tissue — provides direct molecular evidence of target engagement in humans.

The Phase 3 TAZPOWER trial in Barth syndrome did not meet its primary 6-minute walk distance endpoint, which was a setback for clinical development. For research purposes, this does not reduce the value of the Phase 2 mechanistic findings — it contextualizes them as promising signals that require further clinical investigation. SS-31's mechanism (cardiolipin stabilization → ETC supercomplex organization → reduced electron leak → improved ATP synthesis) remains scientifically valid and independently reproducible in preclinical models.

For researchers studying mitochondrial aging specifically, SS-31 is the compound with the most direct mechanistic characterization in human mitochondrial disease contexts — making it the highest-priority choice for research into the mitochondrial dysfunction hallmark of aging.

GHK-Cu ranks third on the unique strength of its breadth. The Pickart & Margolina bioinformatics analysis (2018, *Frontiers in Aging Neuroscience*) identified over 4,000 human genes modulated by GHK-Cu, with the most significantly affected gene sets concentrated in DNA repair, antioxidant defense, mitochondrial function, anti-inflammatory signaling, and extracellular matrix maintenance. This breadth of gene expression modulation means GHK-Cu potentially touches more aging hallmarks simultaneously than any single compound in this comparison.

The human evidence for GHK-Cu is strongest in skin and wound healing contexts: multiple published clinical studies in dermatology have shown GHK-Cu increases dermal collagen synthesis, reduces wrinkle depth, and improves skin thickness — outcomes consistent with its documented gene expression effects on fibroblast activity. Whether these gene expression effects translate to meaningful systemic aging biology beyond the skin remains less well-characterized.

The argument for GHK-Cu in a systemic longevity protocol is essentially the gene expression argument: if a compound modulates 4,000 genes in a direction consistent with aging hallmark improvement, the aggregate effect of those gene expression changes across multiple tissue types could be meaningful for systemic aging biology even if no specific systemic clinical trial exists. This is a valid research hypothesis, but it requires confirmation through studies that go beyond the skin aging context.

MOTS-c ranks fourth based on its mechanistic uniqueness and animal model strength, offset by the complete absence of human clinical trial data. No compound in longevity biology has a more compelling mechanistic story for exercise-independent metabolic programming: MOTS-c is encoded in mitochondrial DNA, translocates to the nucleus under metabolic stress, activates AMPK through the AICAR mechanism, and produces gene expression changes that overlap substantially with those produced by aerobic exercise.

The animal evidence is strong. Lee et al. (2021, *Nature Communications*) demonstrated that MOTS-c injection in aged mice extended lifespan when initiated late in life — one of only a few interventions that show lifespan extension with late-life initiation, which is the clinically most relevant demonstration for a potential human aging intervention. The magnitude of lifespan extension in published rodent studies (approximately 10-20% improvement in median survival) is meaningful, if modest by some longevity intervention benchmarks.

The AMPK activation mechanism is fully characterized at the molecular level and is shared with metformin (the most widely used longevity drug candidate) and exercise — two interventions with the strongest human epidemiological evidence for aging modification. This mechanistic alignment with well-validated longevity pathways is MOTS-c's strongest translational argument.

Epithalon ranks fifth on evidence weight, but is not mechanistically redundant with any compound above it — which makes it the highest-priority addition to a multi-compound longevity protocol that already includes NAD+, SS-31, GHK-Cu, and MOTS-c.

Epithalon is the only compound in this comparison that specifically addresses telomere attrition — the shortening of chromosome-end telomeres with each cell division that ultimately triggers senescence or apoptosis. Khavinson's published research on telomerase activation in human somatic cells (PMID 12589845) provides direct evidence that Epithalon can upregulate hTERT, the catalytic component of telomerase, in human cell culture. Animal lifespan studies show consistent 10-25% extensions in median survival across multiple rodent models.

Epithalon's human evidence ranking (fifth) reflects methodological limitations of Khavinson's cohort studies (observational, non-randomized, Russian single-center) rather than a lack of human research — Epithalon has more human data than MOTS-c. Its unique mechanism justifies including it in a comprehensive longevity protocol as the telomere-targeted component, while the evidence base requires additional RCT confirmation before stronger mechanistic claims can be made.

The most complete longevity research protocols in the published literature use multiple compounds with non-overlapping mechanisms, designed to address multiple aging hallmarks simultaneously. Based on the ranking and mechanistic analysis above, the following combination addresses five distinct hallmarks:

NAD+ → Genomic instability (DNA repair via PARP/sirtuin), nutrient sensing dysregulation (SIRT1-mediated metabolic regulation), mitochondrial dysfunction (PGC-1α-mediated biogenesis)

SS-31 → Mitochondrial dysfunction (cardiolipin stabilization, ETC organization, reduced ROS production)

GHK-Cu → Multiple hallmarks via gene expression remodeling (antioxidant upregulation, proteostasis support, extracellular matrix maintenance, anti-inflammatory signaling)

MOTS-c → Nutrient sensing dysregulation (AMPK activation), mitochondrial dysfunction (mitokine signaling), inflammation (NF-κB suppression)

Epithalon → Telomere attrition (telomerase activation, hTERT upregulation)

This five-compound combination covers at minimum five of the nine aging hallmarks with published mechanistic evidence for each. Head-to-head combination studies in aged animal models are sparse, and the optimal timing, dosing, and combination sequence remain open research questions. For researchers designing combination longevity protocols, this framework provides the mechanistic rationale for each compound's inclusion, while acknowledging that combination synergy requires empirical validation.

All compounds are for research purposes only. Longevity applications in humans require clinical trial frameworks, regulatory oversight, and evidence beyond what currently exists in the published literature.

For compound-specific depth on the top-ranked longevity compounds, see MOTS-c: The Mitochondrial Exercise Mimetic, SS-31 and Cardiolipin Stabilization, NAD+ and Longevity, and SHMOOSE: The Newly Discovered Mitochondrial Microprotein. Researchers sourcing these compounds should review How to Source Research Peptides and Peptide Purity Standards before purchasing.